Join CytoSorbents for a virtual KOL and Analyst-Investor Day, featuring Michael J. Mack, MD (Baylor Scott & White Health), C. Michael Gibson, MS, MD (Harvard University), and Richard Whitlock, MD, PhD, FRCSC (McMaster University) – Principal Investigators of the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) randomized controlled trial – and Michael Schmoeckel, MD (Ludwig Maximilians University of Munich).

These key opinion leaders will address the significant challenge of severe perioperative bleeding in patients undergoing heart surgery while on blood thinners, including Brilinta^®. Notably, they will review the key findings from the pivotal U.S. and Canadian STAR-T trial, investigating the safety and efficacy of DrugSorb^®-ATR (an FDA Breakthrough Designated Device) to mitigate this issue. The topline STAR-T results are scheduled for a breakout presentation at the 104^th American Association of Thoracic Surgery conference in Toronto, Canada on April 28^th, 2024.

Additionally, participants will hear about real-world use and outcomes with antithrombotic drug removal in cardiac surgery in the European Union, where the application is already approved.

Live Q&A sessions will follow the formal presentations.